(NewsDirect)
hVIVO PLC (AIM:HVO) Chief ScientificOfficer Andrew Catchpole speaks to Steve Darling from Proactive afterthe specialist contract research organisation announced it has secureda £6.3 million contract with a biotechnology client for the testingof their antiviral candidate using the hVIVO Human Rhinovirus HumanChallenge Study Model.
The Phase 2aclinical trial is designed as a randomised, double-blinded,placebo-controlled human challenge study and will be conducted athVIVO's advanced quarantine facilities in Canary Wharf. Theprimary objective of this study is to assess the impact of theantiviral candidate on viral load, safety, tolerability, andprophylactic antiviral activity against Human Rhinovirus (HRV)infection in various groups of healthy volunteers.
Catchpole explained that the study isscheduled to begin in the second half of 2024, with revenuerecognition spread across 2024 and 2025. As part of the study, hVIVOwill recruit healthy volunteers who will be subjected to controlledHRV infection. The biotechnology client recognizes the value of humanchallenge studies in rapidly generating early human efficacy data,which has the potential to significantly enhance the clinicalasset's overall value.
Catchpole says the contractunderscores hVIVO's expertise in conducting human challengestudies and its growing role in helping pharmaceutical andbiotechnology companies evaluate the effectiveness of their antiviraltreatments.
Contact Details
ProactiveInvestors
+1 604-688-8158
na-editorial@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.